| Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up FH Schröder, J Hugosson, MJ Roobol, TLJ Tammela, M Zappa, V Nelen, ... The Lancet 384 (9959), 2027-2035, 2014 | 1963 | 2014 |
| Pharmacogenetics: from bench to byte—an update of guidelines JJ Swen, M Nijenhuis, A de Boer, L Grandia, AH Maitland‐van der Zee, ... Clinical Pharmacology & Therapeutics 89 (5), 662-673, 2011 | 1255 | 2011 |
| Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus DA Hesselink, RHN van Schaik, IP Van Der Heiden, M van der Werf, ... Clinical Pharmacology & Therapeutics 74 (3), 245-254, 2003 | 864 | 2003 |
| Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci FR Schumacher, AA Al Olama, SI Berndt, S Benlloch, M Ahmed, ... Nature genetics 50 (7), 928-936, 2018 | 861 | 2018 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing KA Birdwell, B Decker, JM Barbarino, JF Peterson, CM Stein, W Sadee, ... Clinical Pharmacology & Therapeutics 98 (1), 19-24, 2015 | 720 | 2015 |
| A multicenter study of [-2] pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to … WJ Catalona, AW Partin, MG Sanda, JT Wei, GG Klee, CH Bangma, ... The Journal of urology 185 (5), 1650-1655, 2011 | 616 | 2011 |
| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 581 | 2019 |
| CYP3A5 Variant Allele Frequencies in Dutch Caucasians RHN van Schaik, IP van der Heiden, JN van den Anker, J Lindemans Clinical chemistry 48 (10), 1668-1671, 2002 | 414 | 2002 |
| DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis LM Henricks, CATC Lunenburg, FM de Man, D Meulendijks, ... The Lancet Oncology 19 (11), 1459-1467, 2018 | 398 | 2018 |
| Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction DV Conti, BF Darst, LC Moss, EJ Saunders, X Sheng, A Chou, ... Nature genetics 53 (1), 65-75, 2021 | 377 | 2021 |
| Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics FM de Man, AKL Goey, RHN van Schaik, RHJ Mathijssen, S Bins Clinical pharmacokinetics 57, 1229-1254, 2018 | 368 | 2018 |
| Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection FH Jansen, RHN van Schaik, J Kurstjens, W Horninger, H Klocker, ... European urology 57 (6), 921-927, 2010 | 342 | 2010 |
| The prostate health index selectively identifies clinically significant prostate cancer S Loeb, MG Sanda, DL Broyles, SS Shin, CH Bangma, JT Wei, AW Partin, ... The Journal of urology 193 (4), 1163-1169, 2015 | 333 | 2015 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy MP Goetz, K Sangkuhl, HJ Guchelaar, M Schwab, M Province, ... Clinical Pharmacology & Therapeutics 103 (5), 770-777, 2018 | 328 | 2018 |
| Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: a preliminary study ML Becker, LE Visser, RHN van Schaik, A Hofman, AG Uitterlinden, ... Diabetes 58 (3), 745-749, 2009 | 324 | 2009 |
| A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients L Elens, R Bouamar, DA Hesselink, V Haufroid, IP van der Heiden, ... Clinical chemistry 57 (11), 1574-1583, 2011 | 300 | 2011 |
| Interpatient variability in the pharmacokinetics of the HIV non‐nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism D Burger, I Van Der Heiden, C La Porte, M Van Der Ende, P Groeneveld, ... British journal of clinical pharmacology 61 (2), 148-154, 2006 | 290 | 2006 |
| The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation DA Hesselink, R Bouamar, L Elens, RHN Van Schaik, T Van Gelder Clinical pharmacokinetics 53, 123-139, 2014 | 289 | 2014 |
| The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients M Del Re, E Biasco, S Crucitta, L Derosa, E Rofi, C Orlandini, M Miccoli, ... European urology 71 (4), 680-687, 2017 | 284 | 2017 |
| Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus ML Becker, LE Visser, RHN Van Schaik, A Hofman, AG Uitterlinden, ... The pharmacogenomics journal 9 (4), 242-247, 2009 | 280 | 2009 |